Carisma to receive US $ 45 million up-front cash payment and investment by Moderna in the form of a US $ 35 million convertible note
The nutraceutical sector is on the cusp of exponential growth and Covid-19 has accelerated the pace of its applications. Dr R.B Smarta, CMD, Interlink, shares his perspective on the growth opportunities and challenges for the sector
Tecentriq is the first and only cancer immunotherapy approved for NSCLC in the adjuvant setting
Plasmacluster technology significantly inactivates SARS-CoV-2 contained in adherent saliva in an environment with 60% humidity where the physiological protective function is maintained
It measures 9 French (3 millimetres) in diameter upon insertion and removal from the body. While in the heart, it expands to support the heart’s pumping function, providing flow greater than 3.5 L/min
Broadens company’s oncology platform of Targeted Alpha Therapies (TATs)
After a volatile decade in which approvals swung sharply from year to year, 2025’s total pushed past long-term norms, exceeding the 10-year average
The incubator anchored at the company's global headquarters in Raleighla launches alongside an inaugural partnership with Cape Fear BioCapital, a Durham-based seed-stage venture capital firm
The company said the safety profile remained consistent with earlier studies and was considered manageable
M&A activity, IPOs and late-stage investments gain momentum as investors prioritize clinical validation, while early-stage biotech firms continue to face funding challenges
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
